The potential ecological risk of veterinary pharmaceuticals from swine wastewater on freshwater aquatic environment

The impact of pharmaceutical residue transport in the aquatic ecosystem has become an increasing subject of environmental interest due to the inherent bioactivity of trace levels of antibiotics and the negative environmental and public health impact. In this study, three veterinary pharmaceuticals including tetracycline, ivermectin, and salicylic acid were investigated in a piggery effluent from Western Cape, South Africa. Three freshwater organisms' taxonomic groups (Pseudokirchneriella subcapitata, Daphnia magna, and Tetrahymena thermophila) were used to determine the ecological risk of different treated piggery effluent concentration range of 1%, 10%, and 20% and a cocktail mixture of veterinary pharmaceuticals of environmental concerns. The average concentration of veterinary pharmaceuticals was in the range of 47.35, 7.19, and 1.46 μg L^-1 for salicylic acid, chloro-tetracycline, and ivermectin, respectively. P. subcapitata exposed to 20% piggery wastewater effluent at 24- and 48-h EC₅₀ showed a toxicity value of 14.2% and 13.6% (v/v), respectively. The study established the ecological risk of the test compounds as low to medium risk for low-level dose and low concentrations of piggery effluent. The relative sensitivity ranking of the taxa drawn is microalgae > protozoa > Cladocera. The study results demonstrated that a high dose of piggery effluent and mixtures of veterinary pharmaceutical can pose a high risk in freshwater ecosystems. PRACTITIONER POINTS: Transport processes of veterinary antibiotics into the environment were investigated. Dilution effect of the veterinary pharmaceutical on the antibiotic levels exists. High dose of piggery effluent presented an ecological risk.

Validation of Multi-Residue Method for Quantification of Antibiotics and NSAIDs in Avian Scavengers by Using Small Amounts of Plasma in HPLC-MS-TOF

Pharmaceuticals are still considered emerging pollutants affecting both aquatic and terrestrial ecosystems. Scavenging bird species may be exposed to veterinary drugs when they feed on livestock carcasses provided at supplementary feeding stations, as these are often stocked with ailing and/or recently medicated animals. Because those animals may be a source of several different pharmaceutical compounds, analytical methods to evaluate residue levels and exposure potential should enable detection and quantification of as many different compounds as possible, preferably from small sample volumes. Four different extraction methods were tested to conduct HPLC-MS-TOF analysis of some of the most common veterinary drugs used in livestock in Spain. The method deemed most viable was a simple extraction, using methanol and 100 µL of plasma, that allowed quantification of seven antibiotics (tetracycline, oxytetracycline, ciprofloxacin, enrofloxacin, nalidixic acid, trimethoprim, sulfadiazine) and five nonsteroidal anti-inflammatory drugs (NSAIDs) (meloxicam, flunixin, carprofen, tolfenamic acid, phenylbutazone). The method was then applied to analysis of 29 Eurasian griffon vulture (Gyps fulvus) nestling samples, wherein enrofloxacin and tolfenamic acid were most commonly detected (69% and 20%, respectively). To our knowledge, this is the first study including NSAIDs in the exposure assessment of different classes of veterinary pharmaceuticals in live avian scavengers.

Exploring Medication Adherence Using M-Health: A Study from Veterinary Medicine

Background: Pharmacy practice includes the handling of human and animal medication. Amongst veterinary pharmaceutical treatments, the management of Canine Atopic Dermatitis (CAD), a chronic skin condition affecting 10%–15% of the canine population, is complex and demanding. Medication regimens are tailored to each animal and their owner or caregiver. The purpose of this study was to assess the impact of a mobile health (m-health) application (Petable^®) to support the medication adherence in CAD treatment and clinical improvement. Methods: A total of 30 atopic dogs under treatment for CAD and their caregivers were enrolled. Both the dogs’ and owners’ background data were recorded as well as clinical and medication adherence information. This was accomplished by direct observation, clinical files consultation, mobile application, and medication adherence (Medida de Adesão aos Tratamentos—MAT questionnaire) feedback. Results: The overall non-adherence of the sample was 12.6% according to the mobile application, while 60% of caregivers self-scored as adherent according to the MAT. The only significant and positive correlation was between overall adherence and the caregiver’s education. The average degree of pruritus decreased over time and during treatment, independently to the level of m-health app usage. Conclusions: The adherence to chronic treatments may be improved through m-health apps, although further studies are needed to gauge their actual usefulness in supplementing known adherence determinants.

Cell-Based Veterinary Pharmaceuticals - Basic Legal Parameters Set by the Veterinary Pharmaceutical Law and the Genetic Engineering Law of the European Union

Cell-based therapies have been in use in veterinary medicine for years. However, the legal requirement of manufacturing, placing on the market and use of cell-based veterinary pharmaceuticals are not as well developed as the respective requirements of chemical pharmaceuticals. Cell-based veterinary pharmaceuticals are medicinal products in the sense of the pharmaceutical law of the European Union (EU). For that reason, such medicinal products principally require official approval for their manufacture and an official marketing authorization for their placement on the market before being used by the veterinarian. The manufacture, placing on the market, and use of cell-based veterinary pharmaceuticals without manufacturing approval and marketing authorization is permitted only in certain exceptional cases determined by EU and individual Member State law. Violations of this requirement may have consequences for the respective veterinarian under criminal law and under the code of professional conduct in the respective Member State. The regular use of cell-based veterinary pharmaceuticals within the scope of a therapeutic emergency as well as the import of such veterinary pharmaceuticals from non-European countries for use in the EU are currently out of the question in the EU because of a lack of legal bases. Here, we review the general legal requirement of manufacturing, placing on the market, and use of cell-based veterinary pharmaceuticals within the EU and point out different implementations of EU law within the different Member States.

The Occurrence of Veterinary Pharmaceuticals in the Environment: A Review

It is well known that there is a widespread use of veterinary pharmaceuticals and consequent release into different ecosystems such as freshwater bodies and groundwater systems. Furthermore, the use of organic fertilizers produced from animal waste manure has been also responsible for the occurrence of veterinary pharmaceuticals in agricultural soils. This article is a review of different studies focused on the detection and quantification of such compounds in environmental compartments using different analytical techniques. Furthermore, this paper reports the main challenges regarding veterinary pharmaceuticals in terms of analytical methods, detection/quantification of parent compounds and metabolites, and risks/toxicity to human health and aquatic ecosystems. Based on the existing literature, it is clear that only limited data is available regarding veterinary compounds and there are still considerable gaps to be bridged in order to remediate existing problems and prevent future ones. In terms of analytical methods, there are still considerable challenges to overcome considering the large number of existing compounds and respective metabolites. A number of studies highlight the lack of attention given to the detection and quantification of transformation products and metabolites. Furthermore more attention needs to be given in relation to the toxic effects and potential risks that veterinary compounds pose to environmental and human health. To conclude, the more research investigations focused on these subjects take place in the near future, more rapidly we will get a better understanding about the behavior of these compounds and the real risks they pose to aquatic and terrestrial environments and how to properly tackle them.